^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | MTI-31 (mTORC1 inhibitor, mTORC2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial–Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer
Excerpt:
MTI-31 potently inhibited cell proliferation (IC50 <1 μmol/L) and in vivo tumor growth in multiple NSCLC models of EGFR/T790M, EML4-ALK, c-Met, or KRAS (MED <10 mg/kg)....We first assessed antiproliferative activity of MTI-31 in a panel of six NSCLC cell lines, which included representative lines with oncogenic EGFR (HCC827, PC9, and H1975), c-Met (H1993), EML4-ALK (H2228), or KRAS (A549)...
DOI:
10.1158/1078-0432.CCR-18-2548
